Nociceptin Receptor as a Target to Treat Alcohol Use Disorder: Challenges in Advancing Medications Development.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Alcoholism: Clinical and Experimental Research

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/acer.13222PMID 27696442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence.

  2016cited by this paper
• Alcohol Use Disorders in Primary Health Care: What Do We Know and Where Do We Go?

  2016cited by this paper
• Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders.

  2016cited by this paper
• Potential Medications for the Treatment of Alcohol Use Disorder: An Evaluation of Clinical Efficacy and Safety

  2016cited by this paper
• The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research.

  2016cited by this paper
• A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models.

  2016cited by this paper
• Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development.

  2016cited by this paper
• Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe

  2016cited by this paper
• From genetic studies to precision medicine in alcohol dependence

  2016cited by this paper
• Existing and Future Drugs for the Treatment of the Dark Side of Addiction.

  2016cited by this paper
• A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

  2016cited by this paper
• MT‐7716, a potent NOP receptor agonist, preferentially reduces ethanol seeking and reinforcement in post‐dependent rats

  2015cited by this paper
• Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.

  2015cited by this paper
• The pharmacogenetics of alcohol use disorder.

  2015cited by this paper
• Alcoholic liver disease - the extent of the problem and what you can do about it.

  2015cited by this paper
• Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment.

  2015cited by this paper
• Management of Alcohol Use Disorder in Patients Requiring Liver Transplant.

  2015cited by this paper
• Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects

  2015cited by this paper
• Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

  2014cited by this paper
• Topiramate Treatment of Heavy Drinkers: Moderation by a GRIK1 Polymorphism

  2014cited by this paper
• How the Affordable Care Act and Mental Health Parity and Addiction Equity Act Greatly Expand Coverage of Behavioral Health Care

  2014cited by this paper
• Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence.

  2014cited by this paper
• Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate

  2014cited by this paper
• Combined Pharmacotherapies for the Management of Alcoholism: Rationale and Evidence to Date

  2014cited by this paper
• Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study.

  2014cited by this paper
• Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.

  2014cited by this paper
• Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.

  2014cited by this paper
• Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.

  2014cited by this paper
• The NIH BRAIN Initiative

  2013cited by this paper
• Physician education in addiction medicine.

  2013cited by this paper
• Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.

  2013cited by this paper
• Drug-target and disease networks: polypharmacology in the post-genomic era

  2013cited by this paper
• Randomized, Placebo-Controlled Trials of Antidepressants for Acute Major Depression: Thirty-Year Meta-Analytic Review

  2012cited by this paper
• Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

  2012cited by this paper
• Medications development to treat alcohol dependence: a vision for the next decade

  2012cited by this paper
• DNAzyme Targeting c-jun Suppresses Skin Cancer Growth

  2012cited by this paper
• Revolution Stalled

  2012cited by this paper
• Human laboratory paradigms in alcohol research.

  2012cited by this paper
• Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.

  2011cited by this paper
• A dearth of new meds.

  2011cited by this paper
• Trends in the exploitation of novel drug targets

  2011cited by this paper
• Integrating Addiction Medicine Into Graduate Medical Education in Primary Care: The Time Has Come

  2011cited by this paper
• Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.

  2010cited by this paper
• How to improve R&D productivity: the pharmaceutical industry's grand challenge

  2010cited by this paper
• Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.

  2009cited by this paper
• Improving acceptance of naltrexone in community addiction treatment centers: a pilot study.

  2008cited by this paper
• A role for brain stress systems in addiction.

  2008cited by this paper
• Network pharmacology: the next paradigm in drug discovery.

  2008cited by this paper
• What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

  2008cited by this paper
• Drug—target network

  2007cited by this paper
• Trends in the Adoption of Medications for Alcohol Dependence

  2006cited by this paper
• Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats

  2004cited by this paper
• Research to practice: adoption of naltrexone in alcoholism treatment.

  2003cited by this paper
• Molecular cloning of the orphanin FQ receptor gene and differential tissue expression of splice variants in rat.

  2001cited by this paper
• Barriers to the use of medications to treat alcoholism.

  2001cited by this paper
• Nociceptin prevents stress‐induced ethanol‐but not cocaine‐seeking behavior in rats

  2000cited by this paper

• Septo-hypothalamic regulation of binge-like alcohol consumption by the nociceptin system

  2025cites this paper
• NOP-Targeted Nonpeptide Ligands.

  2019cites this paper
• Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice.

  2019cites this paper
• Advances in Pharmacotherapy Development: Human Clinical Studies.

  2018cites this paper